PA Bulletin, Doc. No. 12-12
PA Bulletin, Doc. No. 12-12 | fictitious name registration form dscb 54 311

12 Advice That You Must Listen Before Embarking On Fictitious Name Registration Form Dscb 12 12 | Fictitious Name Registration Form Dscb 12 12

Posted on

Miyamoto S, Lieberman JA, Fleischhacker WW, Aoba A, Marder SR. Antipsychotic drugs. In: Tasman A, Kay J, Lieberman JA (eds). Psychiatry, 2nd edn. John Wiley & Sons, Ltd: Chier, 2003, pp 1928–1964.

PA Bulletin, Doc. No
PA Bulletin, Doc. No | fictitious name registration form dscb 54 311

Buckley PF. Broad ameliorative uses of aberant antipsychotic medications. Biol Psychiatry 2001; 50: 912–924.

Kane JM, Leucht S, Carpenter D, Docherty JP. Able accord guideline series. Optimizing pharmacologic assay of certifiable disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64(Suppl 12): 5–19.

McEvoy JP, Scheifler PL, Frances A. The able accord guideline series: assay of schizophrenia 1999. J Clin Psychiatry 1999; 60: 1–80.

Miyamoto S, Stroup TS, Duncan GE, Aoba A, Lieberman JA. Astute pharmacologic assay of schizophrenia. In: Hirsch SR, Weinberger DR (eds). Schizophrenia, 2nd edn. Blackwell Science, Oxford, 2003, pp 442–473.

Remington G. Understanding antipsychotic ‘atypicality’: a analytic and pharmacological affective target. J Psychiatry Neurosci 2003; 28: 275–284.

Richelson E. Receptor pharmacology of neuroleptics: affiliation to analytic effects. J Clin Psychiatry 1999; 60(Suppl 10): 5–14.

Miyamoto S, Duncan GE, Goff DC, Lieberman JA. Therapeutics of schizophrenia. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Bearing of Progress. Lippincott Williams & Wilkins, Philadelphia, 2002, pp 775–807.

Miyamoto S, Duncan GE, Mailman RB, Lieberman JA. Developing aberant antipsychotic drugs:strategies and goals. Curr Opin CPNS Invest Drugs 2000; 2: 25–39.

Kane JM. Schizophrenia. N Engl J Med 1996; 334: 34–41.

Lewis DA, Lieberman JA. Catching up on schizophrenia: accustomed history and neurobiology. Neuron 2000; 28: 325–334.

Kane JM. The accepted cachet of neuroleptic therapy. J Clin Psychiatry 1989; 50: 322–328.

Sharif ZA. Common assay goals of antipsychotics: astute treatment. J Clin Psychiatry 1998; 59(Suppl. 19): 5–8.

Schulz C, McGorry P. Traditional antipsychotic medications: a analytic use. In: Buckley PF, Waddington JL (eds). Schizophrenia and Mood Disorders: The New Biologic Therapies in Analytic Practice. Butterworth-Heinemann: Woburn, MA, pp 2000; 14–20.

Breier A, Wright P, Birkett M, Meehan K, David, Brook S. A double-blind dosage acknowledgment abstraction comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients, ACNP 39th Annual Meeting Abstract. American College of Neuropsychopharmacology: Puerto Rico, 2000.

Fleischhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural Transm 2003; 64(Suppl): 105–117.

Marder SR, Van Putten T. Antipsychotic medications. In: Schatzberg AF, Nemeroff CB (eds). The American Psychiatric Press Textbook of Psychopharmacology. American Psychiatric Press, Inc.: Washington, DC, pp 1995; 247–261.

Creese I, Burt DR, Snyder SH. Dopamine receptor bounden predicts analytic and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 480–483.

Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic biologic doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717–719.

Seeman P. Dopamine receptors and the dopamine antecedent of schizophrenia. Synapse 1987; 1: 133–152.

Miyamoto S, Mailman RB, Lieberman JA, Duncan GE. Blunted academician metaic acknowledgment to ketamine in mice defective D1A dopamine receptors. Academician Res 2001; 894: 167–180.

Kapur S, Seeman P. Antipsychotic agents adapt in how fast they appear off the dopamine D2 receptors. Implications for aberant antipsychotic action. J Psychiatry Neurosci 2000; 25: 161–166.

Remington G, Kapur S. D2 and 5-HT2 receptor furnishings of antipsychotics: bridging basal and analytic allegation application PET. J Clin Psychiatry 1999; 60(Suppl 10): 15–19.

Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron discharge tomographic assay of axial D1 and D2 dopamine receptor ascendancy in patients advised with classical neuroleptics and clozapine. Affiliation to extrapyramidal ancillary effects. Arch Gen Psychiatry 1992; 49: 538–544.

Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S et al. Aerial levels of dopamine D2 receptor ascendancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153: 948–950.

Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C et al. Axial D2-dopamine receptor ascendancy in affiliation to antipsychotic biologic effects: a double-blind PET abstraction of schizophrenic patients. Biol Psychiatry 1993; 33: 227–235.

Kapur S, Zipursky R, Jones C, Remington G, Houle S. Accord amid dopamine D2 occupancy, analytic response, and ancillary effects: a double-blind PET abstraction of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514–520.

Bigliani V, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Stephenson C et al. In vivo ascendancy of striatal and banausic cortical D2/D3 dopamine receptors by archetypal antipsychotic drugs. epidepride distinct photon discharge tomography (SPET) study. Br J Psychiatry 1999; 175: 231–238.

Xiberas X, Martinot JL, Mallet L, Artiges E, Loc’h C, Maziere B et al. Extrastriatal and striatal D(2) dopamine receptor barricade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001; 179: 503–508.

Nyberg S, Farde L. Non-equipotent doses partly explain differences amid antipsychotics—implications of PET studies. Psychopharmacology 2000; 148: 22–23.

Waddington JL, Kapur S, Remington GJ. The neuroscience and analytic psychopharmacology of first- and second-generation antipsychotic drugs. In: Hirsch SR, Weinberger DR (eds). Schizophrenia, 2nd edn. Blackwell Science: Oxford, 2003, pp 421–441.

Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K et al. The accord amid D2 receptor ascendancy and claret levels on low dosage articulate haloperidol: a PET study. Psychopharmacology 1997; 131: 148–152.

Stip E. Aberant antipsychotics: issues and controversies. Typicality of aberant antipsychotics. J Psychiatry Neurosci 2000; 25: 137–153.

Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: abiding assay elevates dopamine receptor bounden in brain. Science 1977; 196: 326–328.

Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: cogwheel adjustment afterwards 8 months assay with antipsychotic drugs. J Pharmacol Exp Ther 1997; 280: 561–569.

Lee T, Seeman P, Tourtellotte WW, Farley IJ, Hornykeiwicz O. Bounden of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 1978; 274: 897–900.

Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ et al. Added dopamine D2 receptor bounden afterwards abiding assay with antipsychotics in humans: a analytic PET study. Psychopharmacology 2000; 152: 174–180.

Lai H, Carino MA, Horita A. Abiding treatments with zotepine, thioridazine, and haloperidol affect apomorphine-elicited stereotypic behavior and striatal 3H-spiroperidol bounden sites in the rat. Psychopharmacology 1981; 75: 388–390.

Fleminger S, Rupniak NM, Hall MD, Jenner P, Marsden CD. Changes in apomorphine-induced stereotypy as a aftereffect of subacute neuroleptic assay correlates with added D-2 receptors, but not with increases in D-1 receptors. Biochem Pharmacol 1983; 32: 2921–2927.

Bunney BS, Grace AA. Astute and abiding haloperidol treatment: allegory of furnishings on nigral dopaminergic corpuscle activity. Activity Sci 1978; 23: 1715–1728.

Chiodo LA, Bunney BS. Archetypal and aberant neuroleptics: cogwheel furnishings of abiding administering on the action of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3: 1607–1619.

White FJ, Wang RY. Cogwheel furnishings of classical and aberant antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983; 221: 1054–1057.

Mereu G, Lilliu V, Vargiu P, Muntoni AL, Diana M, Gessa GL. Failure of abiding haloperidol to abet depolarization inactivation of dopamine neurons in unanesthetized rats. Eur J Pharmacol 1994; 264: 449–453.

Mereu G, Lilliu V, Vargiu P, Muntoni AL, Diana M, Gessa GL. Depolarization inactivation of dopamine neurons: an artifact? J Neurosci 1995; 15: 1144–1149.

Melis M, Mereu G, Lilliu V, Quartu M, Diana M, Gessa GL. Haloperidol does not aftermath dopamine corpuscle depolarization-block in paralyzed, unanesthetized rats. Academician Res 1998; 783: 127–132.

Moore H, Todd CL, Grace AA. Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons. J Neurosci 1998; 18: 5068–5077.

Boye SM, Rompre PP. Behavioral affirmation of depolarization block of dopamine neurons afterwards abiding assay with haloperidol and clozapine. J Neurosci 2000; 20: 1229–1239.

Grace AA, Bunney BS, Moore H, Todd CL. Dopamine-cell depolarization block as a archetypal for the ameliorative accomplishments of antipsychotic drugs. Trends Neurosci 1997; 20: 31–37.

Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O et al. Neurochemical characteristics of amisulpride, an aberant dopamine D2/D3 receptor adversary with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83–97.

Waddington J, Casey D. Allusive pharmacology of classical and aberant (second-generation) antipsychotics. In: Buckley PF, Waddington JL (eds). Schizophrenia and Mood Disorders: The New Biologic Therapies in Analytic Practice. Butterworth-Heinemann: Woburn, MA, 2000, pp 3–13.

Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological contour of amisulpride: an antipsychotic biologic with presynaptic D2/D3 dopamine receptor adversary action and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 73–82.

Martinot JL, Paillere-Martinot ML, Poirier MF, Dao-Castellana MH, Loc’h C, Maziere B. In vivo characteristics of dopamine D2 receptor ascendancy by amisulpride in schizophrenia. Psychopharmacology 1996; 124: 154–158.

Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc’h C et al. In vivo extrastriatal and striatal D2 dopamine receptor barricade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001; 21: 207–214.

Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ et al. Is regionally careful D2/D3 dopamine ascendancy acceptable for aberant antipsychotic effect? An in vivo quantitative epidepride SPET abstraction of amisulpride-treated patients. Am J Psychiatry 2003; 160: 1413–1420.

Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL. Bounden of antipsychotic drugs to cortical 5-HT2A receptors: a PET abstraction of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998; 155: 505–508.

Seeman P. Aberant antipsychotics: apparatus of action. Can J Psychiatry 2002; 47: 27–38.

Meltzer HY, Matsubara S, Lee JC. Classification of archetypal and aberant antipsychotic drugs on the base of dopamine D1, D2 and Serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238–246.

Lieberman JA. Understanding the apparatus of action of aberant antipsychotic drugs: a assay of compounds in use and development. Br J Psychiatry 1993; 163: 7–18.

Duncan GE, Zorn S, Lieberman JA. Mechanisms of archetypal and aberant antipsychotic biologic action in affiliation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 1999; 4: 418–428.

Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA et al. 5-HT2 and D2 receptor ascendancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155: 921–928.

Kapur S, Zipursky RB, Remington G. Analytic and abstract implications of 5-HT2 and D2 receptor ascendancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286–293.

Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron discharge tomography abstraction of quetiapine in schizophrenia: a basal award of an antipsychotic aftereffect with alone briefly aerial dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57: 553–559.

Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor ascendancy in affiliation to clozapine serum concentration: a PET abstraction of schizophrenic patients. Am J Psychiatry 1995; 152: 1444–1449.

Seeman P, Tallerico T. Antipsychotic drugs which arm-twist little or no parkinsonism bind added about than dopamine to academician D2 receptors, yet absorb aerial levels of these receptors. Mol Psychiatry 1998; 3: 123–134.

Bench CJ, Lammertsma AA, Dolan RJ, Grasby PM, Warrington SJ, Gunn K et al. Dosage abased ascendancy of axial dopamine D2 receptors by the aberant neuroleptic CP-88,059-01: a abstraction application positron discharge tomography and 11C-raclopride. Psychopharmacology 1993; 112: 308–314.

Bench CJ, Lammertsma AA, Grasby PM, Dolan RJ, Warrington SJ, Boyce M et al. The time advance of bounden to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) bent by positron discharge tomography. Psychopharmacology 1996; 124: 141–147.

PA Bulletin, Doc. No
PA Bulletin, Doc. No | fictitious name registration form dscb 54 311

Keck PJ, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP et al. Ziprasidone 40 and 120 mg/day in the astute deepening of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998; 140: 173–184.

Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K et al. An basal haloperidol-controlled dose-finding abstraction of ziprasidone in ailing patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18: 296–304.

Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron discharge tomography studies on D2 and 5-HT2 receptor bounden in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995; 15: 19S–23S.

Fischman AJ, Bonab AA, Babich JW, Alpert NM, Rauch SL, Elmaleh DR et al. Positron discharge tomographic assay of axial 5-hydroxytryptamine2 receptor ascendancy in advantageous volunteers advised with the aberant antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 1996; 279: 939–947.

Marder SR, Meibach RC. Risperidone in the assay of schizophrenia. Am J Psychiatry 1994; 151: 825–835.

Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE et al. Serotonergic base of antipsychotic biologic furnishings in schizophrenia. Biol Psychiatry 1998; 44: 1099–1117.

Carlsson A. Focusing on dopaminergic stabilizers and 5-HT2A receptor antagonists. Curr Opin CPNS Invest Drugs 2000; 2: 22–24.

Kapur S, Seeman P. Does fast break from the dopamine d(2) receptor explain the action of aberant antipsychotics? a new hypothesis. Am J Psychiatry 2001; 158: 360–369.

Seeman P, Tallerico T. Rapid absolution of antipsychotic drugs from dopamine D2 receptors: an account for low receptor ascendancy and aboriginal analytic backsliding aloft abandonment of clozapine or quetiapine. Am J Psychiatry 1999; 156: 876–884.

Meltzer HY. Pre-clinical pharmacology of aberant antipsychotic drugs: a careful review. Br J Psychiatry 1996; 29(Suppl): 23–31.

Newman-Tancredi A, Chaput C, Verriele L, Millan MJ. Clozapine is a fractional agonist at cloned, animal serotonin 5-HT1A receptors. Neuropharmacology 1996; 35: 119–121.

Millan MJ. Improving the assay of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 2000; 295: 853–861.

Keltner NL, Johnson V. Biological perspectives. Aripiprazole: a third bearing of antipsychotics begins? Perspect Psychiatr Care 2002; 38: 157–159.

Evenden JL. Furnishings of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) afterwards again administering on a conditioned abstention acknowledgment (CAR) in the rat. Psychopharmacology 1992; 109: 134–144.

Lucas G, Bonhomme N, De Deurwaerdere P, Le Moal M, Spampinato U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, about-face haloperidol-induced catalepsy in rats apart of striatal dopamine release. Psychopharmacology 1997; 131: 57–63.

Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor barricade increases cortical DA absolution via 5-HT(1A) receptor activation: a accessible apparatus of aberant antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76: 1521–1531.

Li X-M, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and norepinephrine absolution in rat prefrontal cortex, basis accumbens and striatum. Psychopharmacology 1998; 136: 153–161.

Martin-Ruiz R, Puig MV, Celada P, Shapiro DA, Roth BL, Mengod G et al. Ascendancy of serotonergic action in centermost prefrontal case by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci 2001; 21: 9856–9866.

Aghajanian GK, Marek GJ. Serotonin archetypal of schizophrenia: arising role of glutamate mechanisms. Academician Res Academician Res Rev 2000; 31: 302–312.

Tanaka E, North RA. Accomplishments of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophysiol 1993; 69: 1749–1757.

Ase AR, Amdiss F, Hebert C, Huang N, van Gelder NM, Reader TA. Furnishings of antipsychotic drugs on dopamine and serotonin capacity and metaites, dopamine and serotonin transporters, and serotonin1A receptors. J Neural Transm 1999; 106: 75–105.

Tarazi FI, Zhang K, Baldessarini RJ. Olanzapine, quetiapine, and risperidone: abiding furnishings on monoamine transporters in rat forebrain. Neurosci Lett 2000; 287: 81–84.

Ichikawa J, Dai J, O’Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs access cortical acetylcholine absolution afterwards an aftereffect in the basis accumbens or striatum. Neuropsychopharmacology 2002; 26: 325–339.

Deutsch SI, Mastropaolo J, Schwartx BL, Rosse R, Morihisa JM. A ‘glutamatergic hypothesis’ of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989; 12: 1–13.

Javitt DC, Zukin SR. Recent advances in the phencyclidine archetypal of schizophrenia. Am J Psychiatry 1991; 148: 1301–1308.

Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998–1007.

Coyle JT. The glutamatergic dysfunction antecedent for schizophrenia. Harv Rev Psychiatry 1996; 3: 241–253.

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al. Subanesthetic furnishings of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199–214.

Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al. NMDA receptor action and animal cognition—The furnishings of ketamine in advantageous volunteers. Neuropsychopharmacology 1996; 14: 301–307.

Bakshi VP, Geyer MA. Animosity of phencyclidine-induced deficits in prepulse inhibition by the accepted aberant antipsychotic olanzapine. Psychopharmacology 1995; 122: 198–201.

Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K et al. Antipsychotic agents alienate non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 1995; 120: 67–74.

Duncan GE, Leipzig JN, Mailman RB, Lieberman JA. Cogwheel furnishings of clozapine and haloperidol on ketamine-induced academician metaic activation. Academician Res 1998; 812: 65–75.

Wang RY, Liang X. M100907 and clozapine, but not haloperidol or raclopride, anticipate phencyclidine-induced barricade of NMDA responses in cone-shaped neurons of the rat centermost prefrontal cortical slice. Neuropsychopharmacology 1998; 19: 74–85.

Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA. Allegory of the furnishings of clozapine, risperidone, and olanzapine on ketamine-induced alterations in bounded academician metaism. J Pharmacol Exp Ther 2000; 293: 8–14.

Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. Clozapine and haloperidol attune N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 1997; 283: 226–234.

Arvanov VL, Wang RY. Clozapine, but not haloperidol, prevents the anatomic hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administering of phencyclidine. J Pharmacol Exp Ther 1999; 289: 1000–1006.

Bakshi VP, Swerdlow NR, Geyer MA. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the affright response. J Pharmacol Exp Ther 1994; 271: 787–794.

Duncan GE, Sheitman BB, Lieberman JA. An chip appearance of pathophysiological models of schizophrenia. Academician Res Rev 1999; 29: 250–264.

Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A 2003; 100: 13674–13679.

Pietraszek M, Ossowska K. Abiding assay with haloperidol diminishes the phencyclidine-induced sensorimotor gating arrears in rats. Naunyn-Schmiedeberg’s Arch Pharmacol 1998; 357: 466–471.

Ossowska K, Pietraszek M, Wardas J, Nowak G, Zajaczkowski W, Wolfarth S et al. The role of glutamate receptors in antipsychotic biologic action. Amino Acids 2000; 19: 87–94.

Duncan GE, Miyamoto S, Lieberman JA. Abiding administering of haloperidol and olanzapine attenuates ketamine-induced academician metaic activation. J Pharmacol Exp Ther 2003; 305: 999–1005.

Giardino L, Bortolotti F, Orazzo C, Pozza M, Monteleone P, Calza L et al. Aftereffect of abiding clozapine administering on MK801-binding sites in the rat brain: a side-preference action in cortical areas. Academician Res 1997; 762: 216–218.

McCoy L, Cox C, Richfield EK. Antipsychotic biologic adjustment of AMPA receptor affection states and GluR1, GluR2 braid alternative expression. Synapse 1998; 28: 195–207.

Ossowska K, Pietraszek M, Wardas J, Nowak G, Wolfarth S. Abiding haloperidol and clozapine administering increases the cardinal of cortical NMDA receptors in rats. Naunyn-Schmiedeberg’s Arch Pharmacol 1999; 359: 280–287.

Spurney CF, Baca SM, Murray AM, Jaskiw GE, Kleinman JE, Hyde TM. Cogwheel furnishings of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse 1999; 34: 266–276.

Tarazi FI, Florijn WJ, Creese I. Adjustment of ionotropic glutamate receptors afterward subchronic and abiding assay with archetypal and aberant antipsychotics. Psychopharmacology 1996; 128: 371–379.

Tascedda F, Lovati E, Blom JM, Muzzioli P, Brunello N, Racagni G et al. Adjustment of ionotropic glutamate receptors in the rat academician in acknowledgment to the aberant antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology 1999; 21: 211–217.

Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. Abiding furnishings of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic biologic treatment. J Pharmacol Exp Ther 2003; 306: 1145–1151.

Meador-Woodruff JH, King RE, Damask SP, Bovenkerk KA. Cogwheel adjustment of hippocampal AMPA and kainate receptor subunit announcement by haloperidol and clozapine. Mol Psychiatry 1996; 1: 41–53.

Eastwood SL, Porter RH, Harrison PJ. The aftereffect of abiding haloperidol assay on glutamate receptor subunit (GluR1, GluR2, KA1, KA2, NR1) mRNAs and glutamate bounden protein mRNA in rat forebrain. Neurosci Lett 1996; 212: 163–166.

Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ. Adjustment of cortical and subcortical glutamate receptor subunit announcement by antipsychotic drugs. J Neurosci 1995; 15: 2453–2461.

Riva MA, Tascedda F, Lovati E, Racagni G. Adjustment of NMDA receptor subunit abettor RNA levels in the rat academician afterward astute and abiding acknowledgment to antipsychotic drugs. Academician Res Mol Academician Res 1997; 50: 136–142.

Healy DJ, Meador-Woodruff JH. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat case and striatum. Academician Res Mol Academician Res 1997; 47: 331–338.

Tascedda F, Blom JM, Brunello N, Zolin K, Gennarelli M, Colzi A et al. Accentuation of glutamate receptors in acknowledgment to the aberant antipsychotic olanzapine in rats. Biol Psychiatry 2001; 50: 117–122.

Ossowska K, Pietraszek M, Wardas J, Dziedzicka-Wasylewska M, Nowicka D, Wolfarth S. Abiding treatments with haloperidol and clozapine adapt the akin of NMDA-R1 mRNA in the rat brain: an in situ admixture study. Pol J Pharmacol 2002; 54: 1–9.

Schmitt A, Zink M, Muller B, May B, Herb A, Jatzko A et al. Furnishings of abiding antipsychotic assay on NMDA receptor bounden and gene announcement of subunits. Neurochem Res 2003; 28: 235–241.

Kontkanen O, Toronen P, Lakso M, Wong G, Castren E. Antipsychotic biologic assay induces cogwheel gene announcement in the rat cortex. J Neurochem 2002; 83: 1043–1053.

Kim T, Tao-Cheng JH, Eiden LE, Loh YP. Chromogranin A, an ‘on/off’ about-face authoritative dense-core secretory atom biogenesis. Corpuscle 2001; 106: 499–509.

Sudhof TC, Rizo J. Synaptotagmins: C2-domain proteins that adapt film traffic. Neuron 1996; 17: 379–388.

Bultynck G, Vermassen E, Szlufcik K, De Smet P, Fissore RA, Callewaert G et al. Calcineurin and intracellular Ca2 -release channels: adjustment or association? Biochem Biophys Res Commun 2003; 311: 1181–1193.

Braunewell KH, Gundelfinger ED. Intracellular neuronal calcium sensor proteins: a ancestors of EF-hand calcium-binding proteins in chase of a function. Corpuscle Tissue Res 1999; 295: 1–12.

Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Atomic assuming of schizophrenia beheld by microarray assay of gene announcement in prefrontal cortex. Neuron 2000; 28: 53–67.

Bauer R, Mayr A, Lederer W, Needham PL, Kilpatrick IC, Fleischhacker WW et al. Further affirmation that behavioral tests and neuropeptide mRNA and tissue akin alterations can differentiate amid archetypal and aberant antipsychotic drugs. Neuropsychopharmacology 2000; 23: 46–55.

Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y et al. 7-(4-butyloxy)-3,4-dihydro-2(1H)-quino linone (OPC-14597), a new accepted antipsychotic biologic with both presynaptic dopamine autoreceptor agonistic action and postsynaptic D2 receptor afraid activity. J Pharmacol Exp Ther 1995; 274: 329–336.

PA Bulletin, Doc. No
PA Bulletin, Doc. No | fictitious name registration form dscb 54 311

Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA et al. Interactions of the aberant antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612–627.

Semba J, Watanabe A, Kito S, Toru M. Behavioural and neurochemical furnishings of OPC-14597, a aberant antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 1995; 34: 785–791.

Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T et al. Aripiprazole, a aberant antipsychotic, is a high-affinity fractional agonist at animal dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381–389.

Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia—therapeutic implications. Academician Res Academician Res Rev 2000; 31: 342–349.

Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, fractional agonist at the animal 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137–140.

Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al. Aripiprazole, a aberant aberant antipsychotic biologic with a altered and able-bodied pharmacology. Neuropsychopharmacology 2003; 28: 1400–1411.

Bowles TM, Levin GM. Aripiprazole: a new aberant antipsychotic drug. Ann Pharmacother 2003; 37: 687–694.

Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF et al. Dopamine D2 and D3 receptor ascendancy in accustomed bodies advised with the antipsychotic biologic aripiprazole (OPC 14597): a abstraction application positron discharge tomography and raclopride. Neuropsychopharmacology 2002; 27: 248–259.

Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the biologic assay of schizophrenia. Schizophr Bull 1980; 6: 70–87.

American Psychiatric Association. Convenance Guideline for the Assay of Patients with Schizophrenia. Convenance Guidelines for the Assay of Psychiatric Disorders. American Psychiatric Association, Washington, D.C, 2000, pp 299–412.

Fleischhacker WW. New drugs for the assay of schizophrenic patients. Acta Psychiatr Scand 1995; 388(Suppl): 24–30.

Spohn HE, Strauss ME. Affiliation of neuroleptic and anticholinergic medication to cerebral functions in schizophrenia. J Abnorm Psychol 1989; 98: 367–380.

Meltzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologic deficits in schizophrenia: affiliation to amusing action and aftereffect of antipsychotic biologic treatment. Neuropsychopharmacology 1996; 14: 27S–33S.

Collaborative Alive Accumulation on Analytic Balloon Evaluations. Evaluating the furnishings of antipsychotics on acknowledgment in schizophrenia. Collaborative Alive Accumulation on Analytic Balloon Evaluations. J Clin Psychiatry 1998; 59(Suppl 12): 35–40.

Tollefson GD. Cerebral action in schizophrenic patients. J Clin Psychiatry 1996; 57(Suppl 11): 31–39.

Ayuso-Gutierrez JL, del RV. Factors influencing backsliding in the abiding advance of schizophrenia. Schizophr Res 1997; 28: 199–206.

Kane JM. Pharmacologic assay of schizophrenia. Biol Psychiatry 1999; 46: 1396–1408.

Meltzer HY. Abiding furnishings of neuroleptic drugs on the neuroendocrine system. Adv Biochem Psychopharmacol 1985; 40: 59–68.

Gaebel W. Towards the advance of compliance: the acceptation of psycho-education and new antipsychotic drugs. Int Clin Psychopharmacol 1997; 12(Suppl 1): S37–S42.

Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an abnormal ‘atypical’ antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159: 180–190.

Emsley R, Oosthuizen P. The new and evolving pharmacotherapy of schizophrenia. Psychiatr Clin North Am 2003; 26: 141–163.

Markowitz JS, Brown CS, Moore TR. Aberant antipsychotics Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999; 33: 73–85.

Remington G, Kapur S. Aberant antipsychotics:are some added aberant than others? Psychopharmacology 2000; 148: 3–15.

Geddes J, Freemantle N, Harrison P, Bebbington P. Aberant antipsychotics in the assay of schizophrenia: analytical overview and meta-regression analysis. BMJ 2000; 321: 1371–1376.

Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Ability and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to accepted antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68.

Davis JM, Chen N, Glick ID. A meta-analysis of the ability of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553–564.

Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Analytic Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia balloon architecture and agreement development. Schizophr Bull 2003; 29: 15–31.

Kane JM, Gunduz H, Malhortra AK. Additional bearing antipsychotics in the assay of schizophrenia: clozapine. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Accepted Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare: Philadelphia, 2001, pp 209–223.

Carpenter WTJ, Conley RR, Buchanan RW, Breier A, Tamminga CA. Accommodating acknowledgment and ability management: addition appearance of clozapine assay of schizophrenia. Am J Psychiatry 1995; 152: 827–832.

Conley R, Gounaris C, Tamminga C. Clozapine acknowledgment varies in arrears against non-deficit schizophrenic subjects. Biol Psychiatry 1994; 35: 746–747.

Meltzer HY. Clozapine: is addition appearance valid? Am J Psychiatry 1995; 152: 821–825.

Buchanan RW, Gold JM. Abrogating symptoms: diagnosis, assay and prognosis. Int Clin Psychopharmacol 1996; 11(Suppl 2): 3–11.

Collaborative Alive Accumulation on Analytic Balloon Evaluations. Assessing the furnishings of aberant antipsychotics on abrogating symptoms. Collaborative Alive Accumulation on Analytic Balloon Evaluations. J Clin Psychiatry 1998; 59(Suppl 12): 28–34.

Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO et al. Convenance guideline for the assay of patients with schizophrenia, additional edition. Am J Psychiatry 2004; 161: 1–56.

Marder SR, Davis JM, Chouinard G. The furnishings of risperidone on the bristles ambit of schizophrenia acquired by agency analysis: accumulated after-effects of the North American trials. J Clin Psychiatry 1997; 58: 538–546.

Goff DC, Evins AE. Abrogating affection in schizophrenia: neurobiological models and assay response. Harv Rev Psychiatry 1998; 6: 59–77.

Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G. A path-analytical access to differentiate amid absolute and aberrant biologic furnishings on abrogating affection in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245: 45–49.

Tollefson GD, Sanger TM. Abrogating symptoms: a aisle analytic access to a double-blind, placebo- and haloperidol-controlled analytic balloon with olanzapine. Am J Psychiatry 1997; 154: 466–474.

Moller HJ. Neuroleptic assay of abrogating affection in schizophrenic patients. Ability problems and abstruse difficulties. Eur Neuropsychopharmacol 1993; 3: 1–11.

Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The furnishings of aberant antipsychotic drugs on neurocognitive crime in schizophrenia: a assay and meta-analysis. Schizophr Bull 1999; 25: 201–222.

Meltzer HY, McGurk SR. The furnishings of clozapine, risperidone, and olanzapine on cerebral action in schizophrenia. Schizophr Bull 1999; 25: 233–255.

Worrel JA, Marken PA, Beckman SE, Ruehter VL. Aberant antipsychotic agents: a analytical review. Am J Health Syst Pharm 2000; 57: 238–255.

Mortimer AM. Cerebral action in schizophrenia—do neuroleptics accomplish a difference? Pharmacol Biochem Behav 1997; 56: 789–795.

Velligan DI, Miller AL. Cerebral dysfunction in schizophrenia and its accent to outcome: the abode of aberant antipsychotics in treatment. J Clin Psychiatry 1999; 60(Suppl 23): 25–28.

Green MF, Braff DL. Translating the basal and analytic cerebral neuroscience of schizophrenia to biologic development and analytic trials of antipsychotic medications. Biol Psychiatry 2001; 49: 374–384.

Green MF, Marshall BDJ, Wirshing WC, Ames D, Marder SR, McGurk S et al. Does risperidone advance exact alive anamnesis in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154: 799–804.

Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR et al. Neuropsychological change in aboriginal appearance schizophrenia during 12 months of assay with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Accumulation for assay in schizophrenia.. Arch Gen Psychiatry 2000; 57: 249–258.

Weiss E, Kemmler G, Fleischhacker WW. Advance of cerebral dysfunction afterwards assay with second-generation antipsychotics. Arch Gen Psychiatry 2002; 59: 572–573.

Harvey PD, Keefe RS. Studies of cerebral change in patients with schizophrenia afterward aberant antipsychotic treatment. Am J Psychiatry 2001; 158: 176–184.

Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B et al. Neurocognitive furnishings of clozapine, olanzapine, risperidone, and haloperidol in patients with abiding schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018–1028.

Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA et al. The neurocognitive furnishings of low-dose haloperidol: a two-year allegory with risperidone. Biol Psychiatry 2002; 51: 972–978.

Carpenter WT, Gold JM. Addition appearance of assay for acknowledgment in schizophrenia. Biol Psychiatry 2002; 51: 969–971.

Meltzer HY, Sumiyoshi T. Aberant antipsychotic drugs advance acknowledgment in schizophrenia. Biol Psychiatry 2003; 53: 265–267.

Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind allegory with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.

Fleischhacker WW. Clozapine: a allegory with added aberant antipsychotics. J Clin Psychiatry 1999; 60: 30–34.

Conley RR, Kelly DL. Administering of assay attrition in schizophrenia. Biol Psychiatry 2001; 50: 898–911.

Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a assay and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518–526.

Patel JK, Pinals DA, Breier A. Schizophrenia and added psychoses. In: Tasman A, Kay J, Lieberman JA (eds). PSYCHIATRY, 2nd edn. John Wiley & Sons, Ltd: Chier, 2003, pp 1131–1206.

Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind allegory with placebo. Seroquel Abstraction Group. Arch Gen Psychiatry 1997; 54: 549–557.

Dev V, Raniwalla J. Quetiapine: a assay of its assurance in the administering of schizophrenia. Biologic Saf 2000; 23: 295–307.

Chouinard G. Furnishings of risperidone in tardive dyskinesia: an assay of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15: 36S–44S.

Csernansky J, Okamoto A. Risperidone vs haloperidol for blockage of backsliding in schizophrenia and schizoaffective disorders: a abiding double-blind comparison. The 10th Biennial Winter Workshop on Schizophrenia. Davos, Switzerland, 2000.

Tran PV, Dellva MA, Tollefson GD, Beasley CMJ, Potvin JH, Kiesler GM. Extrapyramidal affection and tolerability of olanzapine against haloperidol in the astute assay of schizophrenia. J Clin Psychiatry 1997; 58: 205–211.

Tollefson GD, Beasley CMJ, Tamura RN, Tran PV, Potvin JH. Blind, controlled, abiding abstraction of the allusive accident of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154: 1248–1254.

Ferris P. Ziprasidone. Curr Opin CPNS Invest Drugs 2000; 2: 58–70.

Pennsylvania Corporation Name Registration | Signature | Corporations - fictitious name registration form dscb 54 311
Pennsylvania Corporation Name Registration | Signature | Corporations – fictitious name registration form dscb 54 311 | fictitious name registration form dscb 54 311

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a absolute assay synthesis. Am J Psychiatry 1999; 156: 1686–1696.

Taylor DM, McAskill R. Aberant antipsychotics and weight gain—a analytical review. Acta Psychiatr Scand 2000; 101: 416–432.

Sussman N. Assay of aberant antipsychotics and weight gain. J Clin Psychiatry 2001; 62(Suppl 23): 5–12.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL et al. Ability and assurance of aripiprazole and haloperidol against placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763–771.

Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E et al. Aripiprazole, an antipsychotic with a aberant apparatus of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–690.

Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the blockage of backsliding in counterbalanced patients with abiding schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048–1056.

Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M et al. Ability and assurance of aripiprazole vs. haloperidol for abiding aliment assay afterward astute backsliding of schizophrenia. Int J Neuropsychopharmacol 2003; 6: 325–337.

Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ et al. Aripiprazole in the assay of schizophrenia: assurance and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123–136.

Crismon ML, DeLeon A, Miller AL. Aripiprazole: does fractional dopaminergic agonism construe into analytic benefits? Ann Pharmacother 2003; 37: 738–740.

Sedvall GC, Karlsson P. Pharmacological abetment of D1-dopamine receptor action in schizophrenia. Neuropsychopharmacology 1999; 22: S181–S188.

Goldman-Rakic PS. The appliance of the dopamine-D1 receptor in the cerebral affection of schizophrenia. Neuropsychopharmacology 1999; 21: S170–S180.

Waddington JL. Pre- and postsynaptic D1 to D5 dopamine receptor mechanisms in affiliation to antipsychotic activity. In: Barnes TRE (ed). Antipsychotic Drugs and Their Ancillary Effects. Academic Press, London, 1993, pp 65–85.

Karlsson P, Smith L, Farde L, Harnryd C, Sedvall G, Wiesel FA. Lack of credible antipsychotic aftereffect of the D1-dopamine receptor adversary SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 1995; 121: 309–316.

Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG et al. Cogwheel furnishings of the D1-DA receptor adversary SCH39166 on absolute and abrogating affection of schizophrenia. Psychopharmacology 1995; 121: 317–322.

Karle J, Clemmesen L, Hansen L, Andersen M, Andersen J, Fensbo C et al. NNC 01-0687, a careful dopamine D1 receptor antagonist, in the assay of schizophrenia. Psychopharmacology 1995; 121: 328–329.

Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D1 receptor mechanisms in the cerebral achievement of adolescent developed and age-old monkeys. Psychopharmacology 1994; 116: 143–151.

Cai JX, Arnsten AF. Dose-dependent furnishings of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial alive anamnesis in age-old monkeys. J Pharmacol Exp Ther 1997; 283: 183–189.

Schneider JS, Sun ZQ, Roeltgen DP. Furnishings of dihydrexidine, a abounding dopamine D-1 receptor agonist, on delayed acknowledgment achievement in abiding low dosage MPTP-treated monkeys. Academician Res 1994; 663: 140–144.

Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O et al. Decreased prefrontal dopamine D1 receptors in schizophrenia appear by PET. Nature 1997; 385: 634–636.

Goldman-Rakic PS, Muly III EC, Williams GV. D1 receptors in prefrontal beef and circuits. Academician Res Rev 2000; 31: 295–301.

Williams GV, Goldman-Rakic PS. Accentuation of anamnesis fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376: 572–575.

Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naphisoquinoline: a almighty abounding dopamine D1 agonist absolute a rigid-beta-phenyldopamine pharmacophore. J Med Chem 1996; 39: 549–555.

Castner SA, Williams GV, Goldman-Rakic PS. Changeabout of antipsychotic-induced alive anamnesis deficits by concise dopamine D1 receptor stimulation. Science 2000; 287: 2020–2022.

Nichols DE, Mailman RB. Substituted hexa-hydro[a]phenanthridines. US Patent 1995; 5: 134.

Nichols DE, Mailman RB. Fused isoquinolines as dopamine receptor ligands. US Patent 1999; 5: 110.

Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al. Cloning of the gene for a animal dopamine D4 receptor with aerial affection for the antipsychotic clozapine. Nature 1991; 350: 610–614.

Seeman P, Guan HC, Van Tol HH. Dopamine D4 receptors animated in schizophrenia. Nature 1993; 365: 441–445.

Lahti RA, Roberts RC, Cochrane EV, Primus RJ, Gallager DW, Conley RR et al. Absolute assurance of dopamine D4 receptors in accustomed and schizophrenic afterward academician tissue: a NGD-94-1 study. Mol Psychiatry 1998; 3: 528–533.

Mansbach RS, Brooks EW, Sanner MA, Zorn SH. Careful dopamine D4 receptor antagonists about-face apomorphine-induced barricade of prepulse inhibition. Psychopharmacology 1998; 135: 194–200.

Feldpausch DL, Needham LM, Stone MP, Althaus JS, Yamamoto BK, Svensson KA et al. The role of dopamine D4 receptor in the consecration of behavioral sensitization to amphetamine and accompanying biochemical and atomic adaptations. J Pharmacol Exp Ther 1998; 286: 497–508.

Merchant KM, Gill GS, Harris DW, Huff RM, Eaton MJ, Lookingland K et al. Pharmacological assuming of U-101387, a dopamine D4 receptor careful antagonist. J Pharmacol Exp Ther 1996; 279: 1392–1403.

Danysz W. Sonepiprazole. Curr Opin CPNS Invest Drugs 2000; 2: 97–104.

Kramer MS, Last B, Getson A, Reines SA. The furnishings of a careful D4 dopamine receptor adversary (L-745,870) in acutely certifiable inpatients with schizophrenia. D4 Dopamine Adversary Group. Arch Gen Psychiatry 1997; 54: 567–572.

Bristow LJ, Kramer MS, Kulagowski J, Patel S, Ragan CI, Seabrook GR. Schizophrenia and L-745,870, a aberant dopamine D4 receptor antagonist. Trends Pharmacol Sci 1997; 18: 186–188.

Mansbach RS, Brooks EW, Sanner MA, Zorn SH. Careful dopamine D4 receptor antagonists about-face apomorphine-induced barricade of prepulse inhibition. Psychopharmacology 1998; 135: 194–200.

Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviere ME, Papillon-Downey C. Placebo-controlled abstraction of the D4/5-HT2A adversary fananserin in the assay of schizophrenia. Am J Psychiatry 1999; 156: 419–425.

Rowley M, Bristow LJ, Hutson PH. Accepted and aberant approaches to the biologic assay of schizophrenia. J Med Chem 2001; 44: 477–501.

Schwartz JC, Diaz J, Pilon C, Sokoloff P. Accessible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic biologic actions. Academician Res Academician Res Rev 2000; 31: 277–287.

Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A afterward study. Arch Gen Psychiatry 1997; 54: 225–232.

Witkin J, Gasior M, Acri J, Beekman M, Thurkauf A, Yuan J et al. Aberant antipsychotic-like furnishings of the dopamine D3 receptor agonist, ( )-PD 128,907. Eur J Pharmacol 1998; 347: R1–R3.

Hackling AE, Stark H. Dopamine D3 receptor ligands with adversary properties. Chembiochem 2002; 3: 946–961.

Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M. S33084, a novel, potent, selective, and aggressive adversary at dopamine D(3)-receptors: II. Anatomic and behavioral contour compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000; 293: 1063–1073.

Lacroix LP, Hows ME, Shah AJ, Hagan JJ, Heidbreder CA. Careful animosity at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat antecedent cingulate cortex. Neuropsychopharmacology 2003; 28: 839–849.

Abi-Saab WM, D’Souza DC, Madonick SH, Krystal JH. Targeting the glutamate system. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Accepted Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 304–332.

Goff DC, Coyle JT. The arising role of glutamate in the pathophysiology and assay of schizophrenia. Am J Psychiatry 2001; 158: 1367–1377.

Leeson PD, Iversen LL. The glycine armpit on the NMDA receptor: structure–activity relationships and ameliorative potential. J Med Chem 1994; 37: 4053–4067.

Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA et al. A placebo-controlled balloon of D-cycloserine added to accepted neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21–27.

Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding balloon of D-cycloserine added to neuroleptics for abrogating affection in schizophrenia. Am J Psychiatry 1995; 152: 1213–1215.

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover balloon of glycine accessory assay for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169: 610–617.

Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of abrogating affection in schizophrenia by glycine. Am J Psychiatry 1994; 151: 1234–1236.

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Ability of high-dose glycine in the assay of constant abrogating affection of schizophrenia. Arch Gen Psychiatry 1999; 56: 29–36.

Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153: 1628–1630.

Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover balloon of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45: 512–514.

Hashimoto A, Oka T. Free D-aspartate and D-serine in the beastly academician and periphery. Prog Neurobiol 1997; 52: 325–353.

Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the assay of schizophrenia. Biol Psychiatry 1998; 44: 1081–1089.

Bergeron R, Meyer TM, Coyle JT, Greene RW. Accentuation of N-methyl-D-aspartate receptor action by glycine transport. Proc Natl Acad Sci USA 1998; 95: 15730–15734.

Berger AJ, Dieudonne S, Ascher P. Glycine uptake governs glycine armpit ascendancy at NMDA receptors of excitatory synapses. J Neurophysiol 1998; 80: 3336–3340.

Javitt DC, Sershen H, Hashim A, Lajtha A. Changeabout of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 1997; 17: 202–204.

Javitt DC, Frusciante M. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and actuality abuse. Psychopharmacology 1997; 129: 96–98.

Dant NC. Glutamate uptake. Prog Neurobiol 2001; 65: 1–105.

Gadea A, Lopez-Colome AM. Glial transporters for glutamate, glycine and GABA I. Glutamate transporters. J Neurosci Res 2001; 63: 453–460.

Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Announcement of excitatory amino acerbic abettor transcripts in the thalamus of capacity with schizophrenia. Am J Psychiatry 2001; 158: 1393–1399.

McCullumsmith RE, Meador-Woodruff JH. Striatal excitatory amino acerbic abettor archetype announcement in schizophrenia, bipolar disorder, and above depressive disorder. Neuropsychopharmacology 2002; 26: 368–375.

Schmitt A, Zink M, Petroianu G, May B, Braus DF, Henn FA. Decreased gene announcement of glial and neuronal glutamate transporters afterwards abiding antipsychotic assay in rat brain. Neurosci Lett 2003; 347: 81–84.

Moghaddam B, Adams B, Verman A, Daly D. Activation of glutamatergic neurotransmission by ketamine—a aberant footfall in the alleyway from NMDA receptor barricade to dopaminergic and cerebral disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921–2927.

PA Bulletin, Doc. No
PA Bulletin, Doc. No | fictitious name registration form dscb 54 311

Chavez-Noriega LE, Schaffhauser H, Campbell UC. Metabotropic glutamate receptors: abeyant biologic targets for the assay of schizophrenia. Curr Biologic Ambition CNS Neurol Disord 2002; 1: 261–281.

Moghaddam B, Adams BW. Changeabout of phencyclidine furnishings by a accumulation II metabotrophic glutamate receptor agonist in rats. Science 1998; 281: 1349–1352.

Bubser M, Keseberg U, Notz PK, Schmidt WJ. Cogwheel behavioral and neurochemical furnishings of aggressive and non-competitive NMDA receptor antagonists in rats. Eur J Pharmacol 1992; 229: 75–82.

Hauber W, Andersen R. The non-NMDA glutamate receptor adversary GYKI 52466 counteracts locomotor dispatch and anticataleptic action induced by the NMDA adversary dizocilpine. Naunyn Schmiedeberg’s Arch Pharmacol 1993; 348: 486–490.

Willins DL, Narayanan S, Wallace LJ, Uretsky NJ. The role of dopamine and AMPA/kainate receptors in the basis accumbens in the hypermotility acknowledgment to MK801. Pharmacol Biochem Behav 1993; 46: 881–887.

Sharp JW, Petersen DL, Langford MT. DNQX inhibits phencyclidine (PCP) and ketamine consecration of the hsp 70 calefaction shock gene in the rat cingulate and retrosplenial cortex. Academician Res 1995; 687: 114–124.

Svensson TH, Mathe JM. Aberant antipsychotic-like aftereffect of AMPA receptor antagonists in the rat. Amino Acids 2000; 19: 221–226.

Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facilitative furnishings of the ampakine CX516 on concise anamnesis in rats: correlations with hippocampal neuronal activity. J Neurosci 1998; 18: 2748–2763.

Hampson RE, Rogers G, Lynch G, Deadwyler SA. Facilitative furnishings of the ampakine CX516 on concise anamnesis in rats: accessory of delayed-nonmatch-to-sample performance. J Neurosci 1998; 18: 2740–2747.

Johnson SA, Luu NT, Herbst TA, Knapp R, Lutz D, Arai A et al. Synergistic interactions amid ampakines and antipsychotic drugs. J Pharmacol Exp Ther 1999; 289: 392–397.

Goff D, Berman I, Posever T, Leahy L, Lynch G. A basal dose-escalation balloon of CX 516 (ampakine) added to clozapine in schizophrenia. Schizophr Res 1999; 36: 280.

Marenco S, Egan MF, Goldberg TE, Knable MB, McClure RK, Winterer G et al. Basal acquaintance with an ampakine (CX516) as a distinct abettor for the assay of schizophrenia: a case series. Schizophr Res 2002; 57: 221–226.

Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D et al. Schizophrenia: glutathione arrears in cerebrospinal aqueous and prefrontal case in vivo. Eur J Neurosci 2000; 12: 3721–3728.

Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative accent in neurons with glutathione deficit: affiliation for schizophrenia. Schizophr Res 2003; 62: 213–224.

Janaky R, Ogita K, Pasqualotto BA, Bains JS, Oja SS, Yoneda Y et al. Glutathione and arresting transduction in the beastly CNS. J Neurochem 1999; 73: 889–902.

Goldman-Rakic PS, Lidow MS, Gallager DW. Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in abbey prefrontal cortex. J Neurosci 1990; 10: 2125–2138.

Arnsten AF, Steere JC, Hunt RD. The addition of alpha 2-noradrenergic mechanisms of prefrontal cortical cerebral function. Abeyant acceptation for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53: 448–455.

Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for assiduity cerebral achievement in schizophrenia. Biol Psychiatry 1999; 45: 1–16.

Friedman JI, Adler DN, Davis KL. The role of norepinephrine in the pathophysiology of cerebral disorders: abeyant applications to the assay of cerebral dysfunction in schizophrenia and Alzheimer’s disease. Biol Psychiatry 1999; 46: 1243–1252.

Arnsten AF, Goldman-Rakic PS. Alpha 2-adrenergic mechanisms in prefrontal case associated with cerebral abatement in age-old nonhuman primates. Science 1985; 230: 1273–1276.

Fields RB, Van Kammen DP, Peters JL, Rosen J, Van Kammen WB, Nugent A et al. Clonidine improves anamnesis action in schizophrenia apart from change in psychosis. Basal findings. Schizophr Res 1988; 1: 417–423.

Uhlen S, Muceniece R, Rangel N, Tiger G, Wikberg JE. Allegory of the bounden activities of some drugs on alpha 2A, alpha 2B and alpha 2C-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig. Pharmacol Toxicol 1995; 76: 353–364.

Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves anamnesis in age-old monkeys afterwards allaying or hypotensive ancillary effects: affirmation for alpha-2 receptor subtypes. J Neurosci 1988; 8: 4287–4298.

Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L et al. Guanfacine assay of cerebral crime in schizophrenia. Neuropsychopharmacology 2001; 25: 402–409.

Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM et al. S18327 (1-ethyl]3-phenyl imidazolin-2-one), a novel, abeyant antipsychotic announcement apparent adversary backdrop at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. J Pharmacol Exp Ther 2000; 292: 38–53.

Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ. Simultaneous altitude of serotonin, dopamine and noradrenaline levels in distinct aboveboard case dialysates of freely-moving rats reveals a circuitous arrangement of alternate auto- and heteroreceptor-mediated ascendancy of release. Neuroscience 1998; 84: 413–429.

Litman RE, Su TP, Potter WZ, Hong WW, Pickar D. Idazoxan and acknowledgment to archetypal neuroleptics in treatment-resistant schizophrenia. Allegory with the aberant neuroleptic, clozapine. Br J Psychiatry 1996; 168: 571–579.

Elman I, Goldstein DS, Eisenhofer G, Folio J, Malhotra AK, Adler CM et al. Apparatus of borderline noradrenergic dispatch by clozapine. Neuropsychopharmacology 1999; 20: 29–34.

Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE et al. Aftereffect of COMT Val108/158 Met genotype on aboveboard affiliate action and accident for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917–6922.

Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al. Prefrontal neurons and the analysis of schizophrenia. Biol Psychiatry 2001; 50: 825–844.

Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D et al. Catechol-O-methyltransferase-deficient mice display ually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998; 95: 9991–9996.

Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS et al. Executive subprocesses in alive memory: accord to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003; 60: 889–896.

Liljequist R, Haapalinna A, Ahlander M, Li YH, Mannisto PT. Catechol O-methyltransferase inhibitor tolcapone has accessory access on achievement in beginning anamnesis models in rats. Behav Academician Res 1997; 82: 195–202.

Gasparini M, Fabrizio E, Bonifati V, Meco G. Cerebral advance during Tolcapone assay in Parkinson’s disease. J Neural Transm 1997; 104: 887–894.

Holden C. Neuroscience. Deconstructing schizophrenia. Science 2003; 299: 333–335.

Watkins P. COMT inhibitors and alarmist toxicity. Neurology 2000; 55: S51–S52.

Borges N. Tolcapone-related alarmist dysfunction: implications for use in Parkinson’s ache therapy. Biologic Saf 2003; 26: 743–747.

Rezvani AH, Levin ED. Cerebral furnishings of nicotine. Biol Psychiatry 2001; 49: 258–267.

Simosky JK, Stevens KE, Freedman R. Nicotinic agonists and psychosis. Curr Biologic Ambition CNS Neurol Disord 2002; 1: 149–162.

Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K et al. Schizophrenia, acoustic gating, and nicotinic receptors. Schizophr Bull 1998; 24: 189–202.

Simosky JK, Stevens KE, Adler LE, Freedman R. Clozapine improves amiss inhibitory audition processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology 2003; 165: 386–396.

Simosky JK, Stevens KE, Kem WR, Freedman R. Intragastric DMXB-A, an alpha7 nicotinic agonist, improves amiss acoustic inhibition in DBA/2 mice. Biol Psychiatry 2001; 50: 493–500.

Schreiber R, Dalmus M, De Vry J. Furnishings of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic affright acknowledgment in rats and mice. Psychopharmacology 2002; 159: 248–257.

Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat academician is composed of alpha 4 and beta 2 subunits and is up-regulated by abiding nicotine treatment. Mol Pharmacol 1992; 41: 31–37.

Bontempi B, Whelan KT, Risbrough VB, Rao TS, Buccafusco JJ, Lloyd GK et al. SIB-1553A, ( /-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with accepted cognitive-enhancing properties: furnishings on alive and advertence anamnesis performances in age-old rodents and nonhuman primates. J Pharmacol Exp Ther 2001; 299: 297–306.

Lloyd GK, Menzaghi F, Bontempi B, Suto C, Siegel R, Akong M et al. The abeyant of subtype-selective neuronal nicotinic acetylcholine receptor agonists as ameliorative agents. Activity Sci 1998; 62: 1601–1606.

Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX et al. Allosteric sensitization of nicotinic receptors by galantamine, a new assay action for Alzheimer’s disease. Biol Psychiatry 2001; 49: 279–288.

Albuquerque EX, Santos MD, Alkondon M, Pereira EF, Maelicke A. Accentuation of nicotinic receptor action in the axial afraid system: a aberant access to the assay of Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15(Suppl 1): S19–S25.

Maelicke A. Allosteric accentuation of nicotinic receptors as a assay action for Alzheimer’s disease. Dement Geriatr Cogn Disord 2000; 11(Suppl 1): 11–18.

Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: furnishings on the advance of Alzheimer’s disease. Biol Psychiatry 2001; 49: 289–299.

Allen TB, McEvoy JP. Galantamine for treatment-resistant schizophrenia. Am J Psychiatry 2002; 159: 1244–1245.

Rosse RB, Deutsch SI. Accessory galantamine administering improves abrogating affection in a accommodating with treatment-refractory schizophrenia. Clin Neuropharmacol 2002; 25: 272–275.

MacEwan GW, Ehmann TS, Khanbhai I, Wrixon C. Donepezil in schizophrenia—is it helpful? An beginning architecture case study. Acta Psychiatr Scand 2001; 104: 469–472.

Howard AK, Thornton AE, Altman S, Honer WG. Donepezil for anamnesis dysfunction in schizophrenia. J Psychopharmacol 2002; 16: 267–270.

Buchanan RW, Summerfelt A, Tek C, Gold J. An open-labeled balloon of accessory donepezil for cerebral impairments in patients with schizophrenia. Schizophr Res 2003; 59: 29–33.

Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H et al. A bifold dark placebo controlled balloon of donepezil accessory assay to risperidone for the cerebral crime of schizophrenia. Biol Psychiatry 2002; 51: 349–357.

Bymaster FP. Accessible role of muscarinic receptor agonists as ameliorative agents for psychosis. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Accepted Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 333–348.

Bymaster FP, Felder C, Ahmed S, McKinzie D. Muscarinic receptors as a ambition for drugs alleviative schizophrenia. Curr Biologic Ambition CNS Neurol Disord 2002; 1: 163–181.

Bo NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A et al. Furnishings of xanomeline, a careful muscarinic receptor agonist, on cerebral action and behavioral affection in Alzheimer disease. Arch Neurol 1997; 54: 465–473.

Perry KW, Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Zhang W et al. The muscarinic agonist xanomeline has antipsychotic-like action in animals and in man. Schizophr Res 1999; 36: 117–118.

Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD et al. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like action in rats and mice. Schizophr Res 2000; 42: 249–259.

Chopra GS, Smith JW. Certifiable reactions afterward cannabis use in East Indians. Arch Gen Psychiatry 1974; 30: 24–27.

Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal abstraction of Swedish conscripts. Lancet 1987; 2: 1483–1486.

Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 2001; 107: 173–177.

Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Animated autogenous cannabinoids in schizophrenia. Neuroreport 1999; 10: 1665–1669.

PA Bulletin, Doc. No
PA Bulletin, Doc. No | fictitious name registration form dscb 54 311

De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di M, V. Endocannabinoid signalling in the claret of patients with schizophrenia. Lipids Health Dis 2003; 2: 5.

Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid antecedent of schizophrenia: cerebral impairments due to dysregulation of the autogenous cannabinoid system. Pharmacol Biochem Behav 1997; 56: 803–807.

Poncelet M, Barnouin MC, Breliere JC, Le Fur G, Soubrie P. Barricade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced acknowledgment of basal behaviour in gerbils. Psychopharmacology 1999; 144: 144–150.

Alonso R, Voutsinos B, Fournier M, Labie C, Steinberg R, Souilhac J et al. Barricade of cannabinoid receptors by SR141716 selectively increases Fos announcement in rat mesocorticolimbic areas via bargain dopamine D2 function. Neuroscience 1999; 91: 607–620.

Gueudet C, Santucci V, Soubrie P, Le Fur G. Barricade of neurokinin3 receptors antagonizes drug-induced citizenry acknowledgment and depolarization block of midbrain dopamine neurons in guinea pigs. Synapse 1999; 33: 71–79.

Kamali F. Osanetant Sanofi-Synthelabo. Curr Opin Investig Drugs 2001; 2: 950–956.

Rein W, Arvanitis L. Antipsychotic aftereffect of four altered compounds—results of the metatrial. Eur Neuropsychopharmacol 2003; 13: S95.

Nemeroff CB. Neurotensin: perchance an autogenous neuroleptic? Biol Psychiatry 1980; 15: 283–302.

Binder EB, Kinkead B, Owens MJ, Nemeroff CB. The role of neurotensin in the pathophysiology of schizophrenia and the apparatus of action of antipsychotic drugs. Biol Psychiatry 2001; 50: 856–872.

Kinkead B, Nemeroff CB. Neurotensin: an autogenous antipsychotic? Curr Opin Pharmacol 2002; 2: 99–103.

Vita N, Oury-Donat F, Chalon P, Guillemot M, Kaghad M, Bachy A et al. Neurotensin is an adversary of the animal neurotensin NT2 receptor bidding in Chinese hamster ovary cells. Eur J Pharmacol 1998; 360: 265–272.

Feifel D, Reza TL, Wustrow DJ, Davis MD. Aberant antipsychotic-like furnishings on prepulse inhibition of affright produced by a neurotensin agonist. J Pharmacol Exp Ther 1999; 288: 710–713.

Shilling PD, Richelson E, Feifel D. The furnishings of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav Academician Res 2003; 143: 7–14.

Azzi M, Betancur C, Sillaber I, Spangel R, Rostene W, Berod A. Again administering of the neurotensin receptor adversary SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems. J Neurochem 1998; 71: 1158–1167.

Finberg JP, Youdim MB. Pharmacological backdrop of the anti-Parkinson biologic rasagiline; modification of autogenous academician amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 2002; 43: 1110–1118.

Perenyi A, Goswami U, Frecska E, Arato M, Bela A. L-deprenyl in alleviative abrogating affection of schizophrenia. Psychiatry Res 1992; 42: 189–191.

Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO. Assay of abrogating affection in schizophrenia and schizoaffective ataxia by selegiline accession of antipsychotic medication. A pilot abstraction analytical the role of dopamine. J Nerv Ment Dis 1996; 184: 295–301.

Gupta S, Droney T, Kyser A, Keller P. Selegiline accession of antipsychotics for the assay of abrogating affection in schizophrenia. Compr Psychiatry 1999; 40: 148–150.

Jungerman T, Rabinowitz D, Klein E. Deprenyl accession for alleviative abrogating affection of schizophrenia: a double-blind, controlled study. J Clin Psychopharmacol 1999; 19: 522–525.

Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson’s disease: aishment of apoptosis and consecration of prosurvival genes. Neurotoxicol Teratol 2002; 24: 675–682.

Naoi M, Maruyama W, Youdim MB, Yu P, Boulton AA. Anti-apoptotic action of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology 2003; 11: 175–181.

Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL et al. Immunohistochemical localization of PDE10A in the rat brain. Academician Res 2003; 985: 113–126.

Schmidt CJ, Chapin DS, McCarthy SA, Fujiwara RA, Harms JF, Shrikhande A et al. The neurochemical and behavioral furnishings of papaverine in vivo advance PDE10 inhibition is ‘antipsychotic’. Schizophr Res 2003; 60: 114.

Noda Y, Yamada K, Furukawa H, Nabeshima T. Involvement of nitric oxide in phencyclidine-induced hyperlocomotion in mice. Eur J Pharmacol 1995; 286: 291–297.

Deutsch SI, Rosse RB, Paul SM, Tomasino V, Koetzner L, Morn CB et al. 7-Nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviors in mice. Neuropsychopharmacology 1996; 15: 37–43.

Johansson C, Jackson DM, Svensson L. Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural furnishings on prepulse inhibition and locomotor action in the rat. Psychopharmacology 1997; 131: 167–173.

Wiley JL, Golden KM, Bowen SE. Furnishings of accentuation of nitric oxide on acoustic affright responding and prepulse inhibition in rats. Eur J Pharmacol 1997; 328: 125–130.

Wiley JL. Nitric oxide synthase inhibitors abate phencyclidine-induced disruption of prepulse inhibition. Neuropsychopharmacology 1998; 19: 86–94.

Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB, Fearing K. Methylene dejected accessory assay of schizophrenia. Clin Neuropharmacol 1997; 20: 357–363.

Maurice T, Phan VL, Urani A, Kamei H, Noda Y, Nabeshima T. Neuroactive neurosteroids as autogenous effectors for the sigma1 (sigma1) receptor: pharmacological affirmation and ameliorative opportunities. Jpn J Pharmacol 1999; 81: 125–155.

Roberts E, Bologa L, Flood JF, Smith GE. Furnishings of dehydroepiandrosterone and its sulfate on academician tissue in ability and on anamnesis in mice. Academician Res 1987; 406: 357–362.

Bologa L, Sharma J, Roberts E. Dehydroepiandrosterone and its sulfated acquired abate neuronal afterlife and enhance astrocytic adverse in academician corpuscle cultures. J Neurosci Res 1987; 17: 225–234.

Compagnone NA, Mellon SH. Dehydroepiandrosterone: a abeyant signalling atom for neocortical alignment during development. Proc Natl Acad Sci USA 1998; 95: 4678–4683.

Mao X, Barger SW. Neuroprotection by dehydroepiandrosterone-sulfate: role of an NFkappaB-like factor. Neuroreport 1998; 9: 759–763.

Bastianetto S, Ramassamy C, Poirier J, Quirion R. Dehydroepiandrosterone (DHEA) protects hippocampal beef from oxidative stress-induced damage. Academician Res Mol Academician Res 1999; 66: 35–41.

Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA acknowledgment induced by dehydroepiandrosterone and its aishment by progesterone: furnishings advised via sigma receptors. J Neurosci 1996; 16: 1193–1202.

Debonnel G, Bergeron R, de Montigny C. Potentiation by dehydroepiandrosterone of the neuronal acknowledgment to N-methyl-D-aspartate in the CA3 arena of the rat after hippocampus: an aftereffect advised via sigma receptors. J Endocrinol 1996; 150(Suppl): S33–S42.

Flood JF, Smith GE, Roberts E. Dehydroepiandrosterone and its sulfate enhance anamnesis assimilation in mice. Academician Res 1988; 447: 269–278.

Flood JF, Roberts E. Dehydroepiandrosterone sulfate improves anamnesis in crumbling mice. Academician Res 1988; 448: 178–181.

Flood JF, Morley JE, Roberts E. Memory-enhancing furnishings in macho mice of pregnenolone and steroids metaically acquired from it. Proc Natl Acad Sci USA 1992; 89: 1567–1571.

Reddy DS, Kulkarni SK. The furnishings of neurosteroids on accretion and assimilation of a adapted passive-avoidance acquirements assignment in mice. Academician Res 1998; 791: 108–116.

Maurice T, Junien JL, Privat A. Dehydroepiandrosterone sulfate attenuates dizocilpine-induced acquirements crime in mice via sigma 1-receptors. Behav Academician Res 1997; 83: 159–164.

Tourney G, Erb JL. Banausic variations in androgens and accent hormones in ascendancy and schizophrenic subjects. Biol Psychiatry 1979; 14: 395–404.

Strauss EB, Sands DE, Robibson AM, Tindall WJ, Stevenson WAH. Use of dehydroisoandrosterone in psychiatric treatment: a basal survey. Br Med J 1952; 2: 64–66.

Sands DE. Further studies on endocrine assay in boyhood and aboriginal developed life. J Ment Sci 1954; 100: 211–219.

Strauss EB, Stevenson WAH. Use of dehydroisoandrosterone in psychiatric practice. J Neurol Neurosurg Psychiatry 1955; 18: 137–144.

Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M et al. Dehydroepiandrosterone accession in the administering of negative, depressive, and all-overs affection in schizophrenia. Arch Gen Psychiatry 2003; 60: 133–141.

Vallee M, Purdy RH, Mayo W, Koob GF, Le Moal M. Neuroactive steroids: new biomarkers of cerebral aging. J Steroid Biochem Mol Biol 2003; 85: 329–335.

Vallee M, Mayo W, Le Moal M. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on acquirements and anamnesis in cerebral aging. Academician Res Academician Res Rev 2001; 37: 301–312.

Zou LB, Yamada K, Sasa M, Nakata Y, Nabeshima T. Furnishings of sigma(1) receptor agonist SA4503 and neuroactive steroids on achievement in a adorable arm bewilderment assignment in rats. Neuropharmacology 2000; 39: 1617–1627.

Noda Y, Kamei H, Kamei Y, Nagai T, Nishida M, Nabeshima T. Neurosteroids alleviate conditioned abhorrence stress: an affiliation with sigma receptors. Neuropsychopharmacology 2000; 23: 276–284.

Lieberman JA. Is schizophrenia a neurodegenerative disorder?: a analytic and pathophysiological perspective. Biol Psychiatry 1999; 46: 729–739.

Lieberman J, Chakos M, Wu H, Alvir J, Hoffman E, Robinson D et al. Longitudinal abstraction of academician analysis in aboriginal adventure schizophrenia. Biol Psychiatry 2001; 49: 487–499.

Kasai K, Shenton ME, Salisbury DF, Hirayasu Y, Lee CU, Ciszewski AA et al. Progressive abatement of larboard above banausic gyrus gray amount aggregate in patients with first-episode schizophrenia. Am J Psychiatry 2003; 160: 156–164.

Kasai K, Shenton ME, Salisbury DF, Hirayasu Y, Onitsuka T, Spencer MH et al. Progressive abatement of larboard Heschl gyrus and planum temporale gray amount aggregate in first-episode schizophrenia: a longitudinal alluring resonance imaging study. Arch Gen Psychiatry 2003; 60: 766–775.

Thome J, Foley P, Riederer P. Neurotrophic factors and the maldevelopmental antecedent of schizophrenic psychoses. Assay article. J Neural Transm 1998; 105: 85–100.

Weinberger DR. Implications of accustomed academician development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660–669.

Stahl SM. When neurotrophic factors get on your nerves: assay for neurodegenerative disorders. J Clin Psychiatry 1998; 59: 277–278.

Basile VS, Masellis M, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL. Application of pharmacogenetics to schizophrenia: Arising insights from studies of clozapine acknowledgment and tardive dyskinesia. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Accepted Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 85–110.

Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M et al. Pharmacogenetic anticipation of clozapine response. Lancet 2000; 355: 1615–1616.

Shastry BS. Schizophrenia: a abiogenetic angle (review). Int J Mol Med 2002; 9: 207–212.

Arranz MJ, Kerwin RW. Advances in the pharmacogenetic anticipation of antipsychotic response. Toxicology 2003; 192: 33–35.

Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J et al. Cozapine, olanzapine, risperidone, and haloperidol in patiens with abiding schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255–262.

Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Analytic Antipsychotic Trials in Intervention Effectiveness (CATIE) Project: Schizophrenia balloon architecture and agreement development. Schizophrenia Bull 2003; 29: 15–31.

Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F et al. A PET abstraction of dopamine D2 and serotonin 5-HT2 receptor ascendancy in patients with schizophrenia advised with ameliorative doses of ziprasidone. Am J Psychiatry 2004; 161: 818–825.

PA Bulletin, Doc. No
PA Bulletin, Doc. No | fictitious name registration form dscb 54 311

12 Advice That You Must Listen Before Embarking On Fictitious Name Registration Form Dscb 12 12 | Fictitious Name Registration Form Dscb 12 12 – fictitious name registration form dscb 54 311
| Pleasant for you to my weblog, with this period I will demonstrate in relation to fictitious name registration form dscb 54 311
.

PA Bulletin, Doc. No
PA Bulletin, Doc. No | fictitious name registration form dscb 54 311

 

PA Bulletin, Doc. No
PA Bulletin, Doc. No | fictitious name registration form dscb 54 311
PA Bulletin, Doc. No
PA Bulletin, Doc. No | fictitious name registration form dscb 54 311
ONLINE REGISTRATION of Pennsylvania Registration of FFCHS or Freedom ..
ONLINE REGISTRATION of Pennsylvania Registration of FFCHS or Freedom .. | fictitious name registration form dscb 54 311
PA Bulletin, Doc. No
PA Bulletin, Doc. No | fictitious name registration form dscb 54 311

Gallery for 12 Advice That You Must Listen Before Embarking On Fictitious Name Registration Form Dscb 12 12 | Fictitious Name Registration Form Dscb 12 12